Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study

Posterior reversible encephalopathy syndrome (PRES) is a rare potential immune-related adverse event (irAE) of checkpoint inhibitors. PRES is a disorder that has a variety of clinical and radiological features, which makes it a challenge for advanced practice registered nurses to diagnose. IrAEs suc...

Descripción completa

Detalles Bibliográficos
Autor principal: Barber, Fedricker D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785083/
https://www.ncbi.nlm.nih.gov/pubmed/33426197
http://dx.doi.org/10.4103/apjon.apjon_49_20
_version_ 1783632387663462400
author Barber, Fedricker D.
author_facet Barber, Fedricker D.
author_sort Barber, Fedricker D.
collection PubMed
description Posterior reversible encephalopathy syndrome (PRES) is a rare potential immune-related adverse event (irAE) of checkpoint inhibitors. PRES is a disorder that has a variety of clinical and radiological features, which makes it a challenge for advanced practice registered nurses to diagnose. IrAEs such as PRES require prompt recognition and intervention to optimize clinical outcomes.
format Online
Article
Text
id pubmed-7785083
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-77850832021-01-07 Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study Barber, Fedricker D. Asia Pac J Oncol Nurs Case Report Posterior reversible encephalopathy syndrome (PRES) is a rare potential immune-related adverse event (irAE) of checkpoint inhibitors. PRES is a disorder that has a variety of clinical and radiological features, which makes it a challenge for advanced practice registered nurses to diagnose. IrAEs such as PRES require prompt recognition and intervention to optimize clinical outcomes. Wolters Kluwer - Medknow 2020-11-21 /pmc/articles/PMC7785083/ /pubmed/33426197 http://dx.doi.org/10.4103/apjon.apjon_49_20 Text en Copyright: © 2020 Ann & Joshua Medical Publishing Co. Ltd http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Barber, Fedricker D.
Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study
title Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study
title_full Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study
title_fullStr Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study
title_full_unstemmed Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study
title_short Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study
title_sort identification and management of posterior reversible encephalopathy syndrome in a patient enrolled in an immunotherapy combination phase i clinical trial: a case study
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785083/
https://www.ncbi.nlm.nih.gov/pubmed/33426197
http://dx.doi.org/10.4103/apjon.apjon_49_20
work_keys_str_mv AT barberfedrickerd identificationandmanagementofposteriorreversibleencephalopathysyndromeinapatientenrolledinanimmunotherapycombinationphaseiclinicaltrialacasestudy

Ejemplares similares